

OncoPharm
John Bossaer
OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.
Episodes
Mentioned books

Feb 6, 2020 • 17min
NK - 1 Antagonist Drug Interactions
Drug-drug interactions are a key consideration when determining which NK-1 antagonist to use in patients receiving highly emetogenic chemotherapy. We discuss the issues for (fos)aprepitant, netupitant, & rolapitant.
A nice aprepitant review (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595939/) and the case for an aprepitant-vincristine interaction (https://doi.org/10.1177/1078155219870840).

Jan 30, 2020 • 14min
Tazemetostat
All the need-to-know items about the latest #oncopharm approved drug, tazemetostat, to start the Pod. We end (9:15) with a brief discussion of how gut bacteria may lead to gemcitabine resistance.

7 snips
Jan 23, 2020 • 17min
Bendamustine
Dive into the world of bendamustine, a chemotherapeutic agent known for its unique dual mechanism of action. Discover its impressive efficacy against lymphomas and compare its results with traditional therapies. The discussion also highlights the intricacies of bendamustine's administration and metabolism, emphasizing the impact of CYP1A2 and how smoking can affect treatment outcomes. Plus, learn about the nuances of its different formulations and what makes this drug stand out in cancer treatment.

Jan 16, 2020 • 16min
Avapritinib
New Drug Update! We discuss the efficacy and safety data surrounding avapritinib's approval as well as its likely role in GIST management.

Jan 9, 2020 • 16min
Safety Signals & 6 - MP Hepatotoxicity
How common are upon safety concerns from FDA on newly approved #oncopharm agents? Does the accelerated approval process lead to more safety updates? We discuss (https://doi.org/10.1634/theoncologist.2019-0653).
We also look at a possible way to mitigate 6-MP hepatoxicity (5:45) using allopurinol (https://doi.org/10.1080/10428194.2019.1702183).
Finally (10:55) we review the most recent FDA indications for olaparib and pembrolizumab.

Jan 2, 2020 • 13min
Trastuzumab Deruxtecan
Kicking off the 2020 Pod season with the last FDA-approval of 2019 - trastuzumab deruxtecan.

Dec 26, 2019 • 16min
Enfortumab-vedotin (& Asciminib)
Closing out the year discussing FDA's approval of enfortumab-vedotin for urothelial cancer and a new, but pharmacologically unique, TKI with activity in CML (12:45). Happy New Year!

Dec 19, 2019 • 15min
Arsenic Sauce
The Foundations of #OncoPharm series combines with a thematic critique of an animated Holiday classic to examine the links between The Grinch and Arsenic Trioxide.

Dec 12, 2019 • 21min
ASH '19 Updates
Reviewing pertinent abstracts from ASH's 2019 annual meeting. Abstracts discussed: LBA-1 (blinatumomab), 2640 (venetoclax-azoles interactions), 2639 (FLAG/CLAG vs. CPX-351 in sAML), LBA-6/862/860 (myeloma), and 3310 (PK-targeted dosing of melphalan for autoHSCT). Search here: https://ash.confex.com/ash/2019/webprogram/start.html

Dec 5, 2019 • 17min
Dose Dense AC
The Landmarks in #OncoPharm series returns with dose-dense AC, published in JCO in 2003 by Citron et al.
Link: https://www.ncbi.nlm.nih.gov/pubmed/12668651